Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
10 janv. 2023 08h47 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Company COO Dr. Pañeda will discuss SemaPhoreTM platform’s functionality with mRNA, and:Peptide-based platform for extrahepatic deliveryThe...
Altamira Therapeutics Provides Year-End 2022 Business Update
19 déc. 2022 08h47 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Dec. 19, 2022 (GLOBE NEWSWIRE) --Altamira Therapeutics Provides Year-End 2022 Business Update Strategic BentrioTM partnering or divestiture process enters decisive phasePartnering...
Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results
30 nov. 2022 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- BentrioTM nasal spray launched in Hong Kong by partner Nuance Pharma to help protect against viruses and allergensCOVAMID trial with Bentrio in...
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
30 nov. 2022 08h07 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Initiative is Nuance’s first step in penetrating Chinese market with BentrioTMDensely populated Hong Kong (7.3 million) remains negatively...
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event
10 nov. 2022 08h47 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 10, 2022 (GLOBE NEWSWIRE) -- • TIDES Europe Event will be held on November 16-18, 2022, in Vienna, Austria• Company Chief Development Officer, Covadonga Pañeda, Ph.D., to...
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement
09 nov. 2022 08h47 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs today...
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure
08 nov. 2022 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- • Publication in International Archives of Allergy and Immunology shows rapid onset and long duration of Bentrio’s protective effects in allergic...
Altamira Therapeutics Announces Reverse Stock Split
24 oct. 2022 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Oct. 24, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today...
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets
21 oct. 2022 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Oct. 21, 2022 (GLOBE NEWSWIRE) -- Definitive agreement to sell 90% stake in Company’s Zilentin subsidiary with option to acquire all of Altamira’s remaining inner ear...
Altamira Therapeutics to Participate at RNA Leaders USA Congress
13 oct. 2022 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Event will be held on October 18-19, 2022 in Boston, MASamuel Wickline, MD, Chief Scientific Officer, to present on the advantages of the...